Tzu-Fei Wang

Thrombosis and benign hematology physician at the Ottawa Hospital

[Marc Carrier @MarcCarrier1]

Major scientific highlight from #ISTH2026 in Paris with simultaneous publication in @JAMA_current

The RCT demonstrated that a diagnostic strategy using the YEARS algorithm in patients with cancer and suspected PE was as safe as using CTPA only, and decreased the need of diagnostic imaging by 22%.

https://t.co/sfgkPfaCjs

[Marc Carrier @MarcCarrier1]

🎉 Congratulations to Dr. @sudeeppappur and the entire #EPCATIII team!

A true highlight of #ISTH2026 in Paris: a Late-Breaking Abstract with simultaneous publication in @NEJM.

Practice-changing results showing that aspirin alone after total hip or knee arthroplasty was noninferior to an initial 5-day course of rivaroxaban followed by aspirin for preventing symptomatic VTE, with no clinically meaningful difference in bleeding.

https://t.co/RDvM6MQ2xZ
@ThrombosisCan @canvector @isth

[Professor Susan R Kahn @SusanRKahn1]

Simultaneous presentation and NEJM publication today- congratulations to Suresh Vedantham, @ParpiaSameer and the C-TRACT team

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Tzu-Fei Wang @TzufeiWang]

@Msood99M @MarcCarrier1 @ICESOntario

[Tzu-Fei Wang @TzufeiWang]

Concerned about drug–drug interactions between DOACs and prostate cancer therapies?
New study of ~3000 patients:
➡️ No ↑ thrombosis with DOACs + enzalutamide/ apalutamide
➡️ No ↑🩸with DOAC + abiraterone
Reassuring real-world data! https://t.co/KYMbnzM78B at @JournalCancer

[ISTH @isth]

📣 NEWS: The ISTH announces five global recipients of 2026 Esteemed Career Awards! This award honors leaders in thrombosis and hemostasis whose life-long achievements have shaped the field through scientific excellence.

Learn more: https://t.co/86YvNQvs34

[Johanna Seiden, MD MPH @JohannaSeidenMD]

OCEANIC-STROKE #ISC26 @StrokeAHA_ASA
In pts with nonCE stroke/high risk TIA, asundexian 50 mg dec IS (csHR 0.74; 95% CI 0.65-0.64; p<0.001)
- difference between treatment arms early & continuous
- consistent effect in subgroups
- reduction in mRS >3
- no inc bleeding

[Marc Carrier @MarcCarrier1]

🆕 New in @JAMA_current

🧠🩸 Age-adjusted D-dimer works for DVT too!
In a multinational prospective study (n=3,205), an age-adjusted cutoff safely ruled out DVT, increasing exclusions by +7.4% with 0% failures at 3 months.
📉 Fewer scans, same safety.

https://t.co/dF7ZNfVOVh

[Danielle Roy @daniellee_roy]

Cancer patients face competing risks of clotting and bleeding. Our new European Heart Journal study shows associations with inflammatory and cardiac biomarkers.
@PhilWellsMD1 @TzufeiWang @stevenhawken @MarcCarrier1 @ESC_Journals

https://t.co/6UPqSqwdox

#EHJ #CardioTwitter

[Marc Carrier @MarcCarrier1]

🎉 Congrats to Dr. @saadmysa on her first oral presentation at #ASH25!

Post-hoc AVERT analysis: In cancer patients on apixaban prophylaxis, concurrent antiplatelet/NSAID use ↑ clinically relevant bleeding (HR 1.78) with no VTE benefit.

#VTE #Cancer #Thrombosis

[Marc Carrier @MarcCarrier1]

🔍 #ASH25 Highlight presented by @FCouturaud
Extended-treatment data from RENOVE 📘 (post-hoc): Apixaban vs rivaroxaban after ≥6 months of anticoagulation for VTE.

🩸 Bleeding (5-yr CRB):
• Full dose: 16.5% API vs 14.4% RIVA (aHR 1.02)
• Reduced dose: 11.0% API vs 9.0% RIVA (aHR 1.31)

🩺 Major bleeding: No significant differences at full or reduced dose.
🔁 Recurrent VTE: Similar between drugs across doses.
⬇️ Dose-reduction effect: Consistent ↓ CRB risk for both DOACs.

[Tzu-Fei Wang @TzufeiWang]

#ASH25

[Tzu-Fei Wang @TzufeiWang]

Cancer-associated thrombosis is preventable yet more work is needed for effective implementation! Dr. @MarcCarrier1 elegantly presented the evidence of primary VTE proph, potential implementation barriers and education and patient-centered pathway can improve outcomes!

[Tzu-Fei Wang @TzufeiWang]

#ASH2025

[Tzu-Fei Wang @TzufeiWang]

#ASH25

[Tzu-Fei Wang @TzufeiWang]

Dr. Houghton provided a comprehensive summary of risks of VTE, prevention and treatment of VTE in patients with hematological malignancy #ASH2025

[Marc Carrier @MarcCarrier1]

🩸 API-CAT Post-hoc of @isabellemahe1 at #ASH25
Predictors of clinically relevant bleeding during extended apixaban for cancer-associated VTE:
📉 Anemia/Thrombocytopenia ↑ risk (HR 1.93)
👴 Age ≥75 ↑ (1.51)
🫁 Index PE ↑ (1.47)
♂️ Male sex ↑ (1.38)
Findings consistent across cancer types.
@LancetHaem
https://t.co/8nebHwymdP

[Marc Carrier @MarcCarrier1]

💉 New in @AjHematology - The WAVe Study 🩸

In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing.

📖 Read: https://t.co/LyRHYEapj2